Medicines Guidance A-Z | Right Decisions

NHSGGC Clinical guidelines are developed by NHSGGC clinicians with the support of clinical governance. The clinical guideline framework sets out how NHSGGC develops, reviews, approves and monitors clinical guidelines. If a guideline on the clinical guideline platform is past its review date, it is currently undergoing the review process as per the clinical guideline framework.

Acute management of people who use drugs (MHS MRG 11)

Administration & Supply of medicines using a PGD SOP (MHS MRG 47)

Alcohol withdrawal - in patient management protocol (MHS MRG 27)

Anaphylaxis recognition and management MHS 32 (482)

Antidepressants - stopping & switching (MHS MRG 32)

Antipsychotics - combination and augmentation guidance (MHS MRG 16)

Antipsychotics - depot long-acting injection prescribing algorithm (MHS MRG 05)

Antipsychotics - effective use of first generation depot injections (MHS MRG 04)

Antipsychotics - high dose monitoring policy (MHS 34)

Antipsychotics - prescribing in dementia (MHS 31)

Antipsychotics - use of depot and long acting injections (MHS 30)

Attention Deficit and Hyperactivity Disorder- treatment (MHS MRG 54)

Benzatropine - protocol for unlicensed use (MHS MRG 18)

Clarithromycin & QTc prolongation alert

Clozapine - 15 day titration regime BLANK (MHS MRG 03.03.02)

Clozapine - 15 day titration regime STANDARD (MHS MRG 03.03.01)

Clozapine - developing a treatment plan for managing off licence use (MHS MRG 03.04)

Clozapine - options for initiation (MHS MRG 03.03)

Clozapine - out patient prescription form (MHS MRG 03.05)

Clozapine - patient holiday supplies (MHS MRG 03.10)

Clozapine - patient information standards (MHS MRG 03.09)

Clozapine - planned withdrawal (MHS MRG 3.12)

Clozapine - plasma monitoring guidance (MHS MRG 03.07)

Clozapine - protocol for rechallenge following a neutropenic episode (MHS MRG 03.11)

Clozapine - protocol for the use of clozapine liquid (MHS MRG 03.06)

Clozapine - protocol for use of oro-dispersible tablets (MHS MRG 3.15)

Clozapine - re-titration following a treatment break (MHS MRG 3.14)

Clozapine- safe use in an aging population (MHS MRG 3.16)

Clozapine - service standards (MHS MRG 03.01)

Clozapine induced constipation - assessment and treatment (MHS MRG 03.08)

Cognitive enhancers- physical health monitoring (MHS MRG 44)

Controlled drugs - advice for checking stock (MHS MRG 10)

Controlled Drug Prescription Requirements (MHS MRG 55)

Covert medication and dysphagia - safe and cost effective administration (MHS MRG 02)

Covert medication policy (MHS 53)

Depression treatment, for adults in primary care (036)

Desirable drug- procedure for ordering and reconciling (MHS MRG 38)

Difficult-to-treat depression pathway (MHS MRG 49)

Emergency cupboard list and procedure for out of hours access (MHS MRG 12)

Extended passes- protocol for managing medication (MHS MRG 51)

Extrapyramidal side effects- Management (MHS MRG 43)

Fluphenazine decanoate - protocol for unlicensed use (MHS MRG 35)

Glasgow Antipsychotic Side-effect Scale (GASS)

Haloperidol and QTc interval prolongation (MHS MRG 07)

In-patient controlled drug administration SOP (MHS MRG 39)

In-patient medication administration SOP (MHS MRG 40)

Insomnia - management (MHS 35)

Insulin - safer use (MHS MRG 21)

Intramuscular medication for acutely disturbed behaviour (MHS 40)

Lithium - good practice standards (MHS MRG 26)

Lithium bundle (MHS MRG 24)

Lithium- community bundle (MHS MRG 45)

Lithium- patient information standards (MHS MRG 34)

Medication given out with prescribed times - administration and recording (MHS MRG 15)

Neuroleptic malignant syndrome (MHS MRG 31)

Non-formulary and unlicensed medicines - advice on access (MHS MRG 08)

Non-formulary request form (MHS MRG 08.01)

Nurse dispensing outwith pharmacy hours (MHS MRG 14)

Off-label unlicensed prescribing guidance in MHS (MHS MRG 25)

Olanzapine- guidance for the use of olanzapine embonate LAI (MHS MRG 37)

Opioids - safer use (MHS MRG 22)

Paracetamol overdose guidance (MHS MRG 17)

Pass medication- procedure for ordering (MHS 37)

Patient Group Directive- Diazepam (MHS MRG 51)

Patient Group Directive- Promethazine (MHS MRG 52)

Patient Group Directive- Zopiclone (MHS MRG 53)

Patients own drugs - procedure for use (MHS 38)

Physical healthcare policy (MHS 20)

Pirenzepine - protocol for unlicensed use (MHS MRG 19)

Prescribing as required psychotropic drugs (MHS MRG 28)

Primary care psychotropic good practice guidance (MHS MRG 46)

Procedure for Ordering and Reconciling PGDs (MHS MRG 48)

Psychotropic Medicines: Reviewing with Care Home Residents (547)

Response ward emergency tray locations (MHS MRG 13)

Safe identification of patients- Policy & procedure (MHS 21)

Safe secure handling of medicines in hospital wards (MHS MRG 01)

Self Medication Programme Guidance (MHS MRG 56)

Serotonin syndrome (MHS MRG 30)

Symptomatic relief policy - adults and older adults (MHS 28)

Thioridazine - protocol for unlicensed use (MHS MRG 20)

Transport of medicines in the community (MHS 39)

Trazodone appropriate formulation choice and use guide (585)

Use of a second staff member 'runners' to deliver medication to the patient

Use of multi-dose compliance aids- good practice statement (MHS MRG 36)

Valproate- use within Mental Health Services (MHS MRG 41)

Zuclopenthixol Acetate (Clopixol Acuphase) (MHS 33)